Clinical Trials Logo

Clinical Trial Summary

This research study is looking at biomarkers in urine samples from patients with Wilms tumor. Studying samples of urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To characterize the urinary metabolite signature of 10 stage III, favorable-histology, Wilms tumor patients from the Cooperative Human Tissue Network (CHTN) Databank, as distinct from 10 normal controls.

II. To characterize and compare the urinary metabolite profile in 50 randomly selected, stage III, favorable-histology, Wilms tumor patients enriched with an additional 30 stage III Wilms tumor patients who have relapsed.

III. To establish if the potential poor outcome (defined as relapse) in the favorable-histology group has a specific metabolite signature.

IV. To characterize the urinary metabolite signature of Wilms tumor in patients with unfavorable histology (diffuse anaplasia) and compare it to those with favorable histology.

OUTLINE:

Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance (NMR) spectroscopy and principal component analysis (PCA). Tumor tissue may also be examined by NMR and PCA. ;


Study Design

Observational Model: Case Control, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT01614808
Study type Observational
Source Children's Oncology Group
Contact
Status Completed
Phase N/A
Start date June 2012
Completion date June 2012

See also
  Status Clinical Trial Phase
Completed NCT01118078 - Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor N/A
Completed NCT01305200 - Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Phase 3
Completed NCT00101270 - Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Phase 1
Completed NCT01502410 - Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Phase 2
Completed NCT00831844 - Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Phase 2
Active, not recruiting NCT00638898 - Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor Phase 1
Completed NCT01586104 - Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases N/A
Completed NCT00897637 - Gene Expression Profiles to Categorize Wilms Tumors N/A
Completed NCT00331643 - Ixabepilone in Treating Young Patients With Refractory Solid Tumors Phase 2
Completed NCT00309907 - Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Phase 2
Completed NCT00012181 - Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas Phase 1